As might be expected with a novel targeted agent, the combinatorial efficacy of BRD4 inhibitors and immune checkpoint inhibitors in solid tumors has been studied in the past and has been mostly attributed to direct tumor effects of BRD4 inhibition (56–60). Here, BRD4 is linked to neoplasm.